Skip to content

XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Coronavirus – COVID-19 Program
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Presentations
    • Media
    • Independent Research
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search

XORTX to Present at NobleConXV Noble Capital Markets’ 15th Annual Investor Conference

  • January 28, 2019December 22, 2020
  • by aaronbb

CALGARY, Alberta, Jan. 28, 2019 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease (PKD), is pleased to announce that Dr. Allen Davidoff, XORTX’s CEO will present at NobleConXV – Noble Capital Markets’ 15th Annual Investor Conference at 9:30 am EST.  A video webcast of the presentation will be available Tuesday, January 29th at the following link, http://noble.mediasite.com/mediasite/Play/901e7d39fbf3435b93b1737e29673ea11d.  The webcast will be archived on the Company’s website, the NobleCon website and on Channelchek.com for 90 days following the event.

The NobleConXV conference is focused on emerging growth companies and attracts a wide range of investors from larger institutional portfolio managers to single family offices.  Noble Capital Markets is an equity-research driven, full service, investment and merchant banking boutique focused on emerging growth companies.  

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease.  XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease.  Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease. Additional information on XORTX Therapeutics is available at www.xortx.com.

For further information, please contact:

Dr. Allen Davidoff, CEO

adavidoff@xortx.com or +1 403 455 7727

or Erik Matthews, Corporate Communications & Investor Relations

info@xortx.com or +1 747 203 5240

The CSE has neither approved nor disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Google+ (Opens in new window)

Related

XORTX Receives FDA Response on Orphan Drug Designation Application
XORTX Signs LOI for Co-Development and Licensing Agreement with Japan’s Teijin Pharma Limited

Press Releases

  • XORTX Confirms $1 Million in Warrant Exercise Proceeds March 2, 2021
  • XORTX Confirms $1 Million in Warrant Exercise Proceeds March 2, 2021
  • XORTX Participating in WuXI Healthcare Forum March 1, 2021
  • XORTX to Present at BIO CEO and Investor Conference February 17, 2021
  • XORTX Closes Over Subscribed Private Placement February 10, 2021

Archives

  • 2012 Press Releases 3
  • 2014 Press Releases 2
  • 2015 Press Releases 1
  • 2017 Press Releases 2
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress